ClinicalTrials.gg
RecruitingNCT06531317EEG-INSIGHTUpdated Jul 31, 2024

Machine-Learning Based EEG Biomarkers for Personalized Interventions

An observational study in Neuropathic Pain, Spinal Cord Injuries and Central Neuropathic Pain, sponsored by Institut Guttmann. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by Institut Guttmann · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
58
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Neuralgia with a site in Spain — 3 open to participants now, 4 under way, 1 of them phase 3. Neuralgia · Spain.

Started
2023
with 2 others
Observational
4 of 32
1 open now
Registered
28th of 32
by date
Lead sponsor
2 of 32
Institut Guttmann

Among the 32 studies in Neuralgia with a site in Spain, this one is one of 3 that started in 2023, is one of 4 observational ones, and was the 28th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

3 of the 32 studies in Neuralgia with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Neuralgia with a site in Spain, or all of them as a file.
02

Study summary

The goal of this observational study is to develop a machine learning model to predict the outcome of a transcranial direct current stimulation (tDCS) treatment in patients suffering from neuropathic pain derived from a spinal cord injury. The main question it aims to answer is:

  • Can electroencephalography (EEG) and clinical assessment data predict the success of tDCS treatment in neuropathic pain patients?

Participants will:

  • Undergo EEG recording sessions to collect brain activity data before treatment.
  • Complete clinical assessments, including medical diagnostics and questionnaires focused on factors related to neuropathic pain before and after treatment.
Read the detailed description

This project aims to develop an artificial intelligence model to predict the response to a neuromodulation treatment (transcranial Direct Current Stimulation, tDCS) for neuropathic pain (NP) following spinal cord injury (SCI), based on electroencephalographic (EEG) signals and clinical assessments. The project consists of two stages:

Stage 1 involves an open trial where participants with SCI and NP will receive neuromodulation treatment at our center, with data collected before and after treatment.

Pre-Treatment Evaluation:

  • Clinical assessment through interviews and validated questionnaires targeted at factors associated with neuropathic pain, depression, and other relevant components.
  • EEG recording using a 64-channel device (Brain Products GmbH, Germany). EEG will be recorded in a soundproof room with participants in a resting state, first with eyes open for 5 minutes and then with eyes closed for another 5 minutes. Participants will be asked to avoid alcohol 12 hours prior and caffeine 3 hours before the recording.

Neuromodulation Treatment:

  • The treatment protocol involves 10 sessions of non-invasive stimulation, each lasting 30 minutes.
  • tDCS will be administered using a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland) with 6 cm² saline-saturated circular electrodes.
  • The anode will be placed over C3 (EEG 10/20 system) to stimulate the primary motor cortex (M1) and the cathode over the contralateral supraorbital area (FP2).
  • For asymmetric pain, stimulation will be applied to the M1 contralateral to the more painful hemibody. For symmetric pain, the dominant hemisphere (C3) will be stimulated.
  • Maximum current delivered will be 2 mA (current density: 0.06 mA/cm²).
  • Sessions will be held once daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation .

Post-Treatment Evaluation:

  • Conducted through interviews and the same validated questionnaires used in the pre-treatment assessment.

As part of the intervention, participants will undergo EEG recording to study the brain's bioelectrical activity non-invasively. Active surface electrodes with electrode gel will be used to enhance skin conductivity. EEG recordings will be conducted at rest, with participants looking at a blank wall in a soundproof room, for 5 minutes with eyes open and 5 minutes with eyes closed.

Stage 2 involves developing a predictive model to classify patients based on their response to the neuromodulation treatment. The model will use metrics derived from pre-treatment EEG recordings and clinical assessments conducted before and after the treatment, with the goal of predicting which patients will respond favorably to tDCS.

EEG preprocessing will be performed by means of the Python programming language, using a custom-made preprocessing pipeline based on the MNE-Python library including: selective outlier channel and segment elimination, frequency filters, supervised auto-labeled independent component analysis for the elimination of muscular and ocular activity, and detection of bridged electrodes.

The EEG recordings will be analyzed using metrics derived from the frequency, complexity and connectivity of the EEG signal. These metrics were selected due to their demonstrated potential in related publications, which highlight the capability of these features to capture differences between groups, either between treatment responders and non-responders, or between healthy subjects and those suffering from NP, among others. Based on these EEG features and other features derived from patient questionnaires, a feature selection process based on metric independence and relevance in previous literature will be carried out in order to maximize model generalizability.

A machine learning (ML) model, with the main candidate model being a support vector machine (SVM), will be used in order to classify between responders and non-responders. The model will be validated by means of k-fold cross-validation. Given satisfactory results, an undersampling of EEG channels (adhering to typical 10:20 setups) will be used to evaluate whether an EEG with less electrodes can yield similar predictive results, thus reducing the need for EEG systems with a high electrode count.

03

Conditions studied

  • Neuropathic Pain
  • Spinal Cord Injuries
  • Central Neuropathic Pain

Keywords

  • Neuropathic Pain
  • EEG
  • Machine Learning
  • Spinal Cord Injury
  • tDCS
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with spinal cord injury (SCI) suffering from neuropathic pain (NP).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Over 18 years old.
  • Neuropathic Pain (NP): Subacute NP at or below the lesion level for at least 1 month following spinal cord injury or disease. Persistent NP is defined as pain in an area of sensory abnormality corresponding to the spinal cord injury according to international criteria (Bryce et al. 2012). The pain should not be primarily related to spasms or any other movement.
  • Pain Intensity: At least 4 out of 10 on the Numerical Rating Scale (NRS) at the time of screening (rated during the previous 24 hours).
  • Pharmacological Treatment: Stable treatment including antiepileptic, antidepressant, or antispastic drugs (Gabapentin (GBP) with a minimum dose of 900 mg/day, Pregabalin (PGB) with a minimum dose of 150 mg/day, Amitriptyline with a minimum dose of 25 mg/day). No dose changes for at least 2 weeks prior to treatment and no additional antiepileptic medication. The pharmacological regimen must be maintained without changes during the 10-day stimulation period and until the electrophysiological measurement. It is recommended to keep the regimen stable until the completion of the following two evaluations (4 and 12 weeks after the end of treatment). Only paracetamol or anti-inflammatory drugs are allowed as rescue treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe pain (NRS > 7) from other sources, such as musculoskeletal pain, inflammatory pain, or cancer-related pain.
  • Subjects with traumatic brain injury.
  • Subjects with alcohol abuse.
  • Subjects with neurological diseases other than the specified spinal cord injury.
  • Subjects with substance abuse.
  • Subjects with any other chronic medical condition where transcranial tDCS is relatively , such as pregnancy or epilepsy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
58 participants (estimated)
Patient registry
No

Groups and cohorts

  • NP Subjects

    Subjects suffering from NP pain after an SCI. Will receive a tDCS treatment.

    Device: transcranial Direct Current Stimulation · Diagnostic Test: Electroencephalography

Interventions

  • Devicetranscranial Direct Current Stimulation

    The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).

    Also known as: tDCS, tCS

  • Diagnostic testElectroencephalography

    64-channel active-electrode EEG with impedances kept \~5KOhm

    Also known as: EEG

06

What researchers measure

Primary outcomes

  1. Patient Improvement as assessed by a composite score

    Composite Score Breakdown: Neuropathic Pain Symptom Inventory (NPSI) Items: * Constant pain intensity: Questions 1, 2, 3, 11, 12 (sum) * Constant pain persistence/frequency: Question 4 * Pain crisis intensity: Questions 5, 6 (sum) * Pain crisis frequency: Question 7 * Allodynia: Questions 8, 9, 10 (sum) Criteria: * Numerical NPSI items are only used where pre-treatment pain ratings are 4/10 or higher. * Responder: Any NPSI item shows a 50% or larger reduction. Brief Pain Inventory (BPI) Items: * Pain Interference: Questions 3a - 3g (average) Criteria: * Responder: 30% improvement or more. Summary: A subject is considered a responder if BOTH of these conditions are met: 1. Improvement of 50% or more in pain intensity or frequency (NPSI). 2. Improvement of 30% or more in pain interference (BPI).

    Time frame: After tDCS treatment (compared to score before tDCS treatment)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gewandter JS, McDermott MP, Evans S, Katz NP, Markman JD, Simon LS, Turk DC, Dworkin RH. Composite outcomes for pain clinical trials: considerations for design and interpretation. Pain. 2021 Jul 1;162(7):1899-1905. doi: 10.1097/j.pain.0000000000002188. No abstract available. PubMed 33449513 ↗
  • Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP, Kronberg G, Truong D, Boggio P, Brunoni AR, Charvet L, Fregni F, Fritsch B, Gillick B, Hamilton RH, Hampstead BM, Jankord R, Kirton A, Knotkova H, Liebetanz D, Liu A, Loo C, Nitsche MA, Reis J, Richardson JD, Rotenberg A, Turkeltaub PE, Woods AJ. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-661. doi: 10.1016/j.brs.2016.06.004. Epub 2016 Jun 15. PubMed 27372845 ↗
  • Zhdanov A, Atluri S, Wong W, Vaghei Y, Daskalakis ZJ, Blumberger DM, Frey BN, Giacobbe P, Lam RW, Milev R, Mueller DJ, Turecki G, Parikh SV, Rotzinger S, Soares CN, Brenner CA, Vila-Rodriguez F, McAndrews MP, Kleffner K, Alonso-Prieto E, Arnott SR, Foster JA, Strother SC, Uher R, Kennedy SH, Farzan F. Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. JAMA Netw Open. 2020 Jan 3;3(1):e1918377. doi: 10.1001/jamanetworkopen.2019.18377. PubMed 31899530 ↗
  • Vuckovic A, Gallardo VJF, Jarjees M, Fraser M, Purcell M. Prediction of central neuropathic pain in spinal cord injury based on EEG classifier. Clin Neurophysiol. 2018 Aug;129(8):1605-1617. doi: 10.1016/j.clinph.2018.04.750. Epub 2018 May 23. PubMed 29886266 ↗
  • Mussigmann T, Bardel B, Lefaucheur JP. Resting-state electroencephalography (EEG) biomarkers of chronic neuropathic pain. A systematic review. Neuroimage. 2022 Sep;258:119351. doi: 10.1016/j.neuroimage.2022.119351. Epub 2022 Jun 2. PubMed 35659993 ↗
  • Mari T, Henderson J, Maden M, Nevitt S, Duarte R, Fallon N. Systematic Review of the Effectiveness of Machine Learning Algorithms for Classifying Pain Intensity, Phenotype or Treatment Outcomes Using Electroencephalogram Data. J Pain. 2022 Mar;23(3):349-369. doi: 10.1016/j.jpain.2021.07.011. Epub 2021 Aug 21. PubMed 34425248 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Nov 2025, 25 months after the start.

Of 77 non-industry observational studies under Neuralgia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 25 months is above that.

Counting every sponsor, half of 88 studies reached it within 18 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2024
First posted
Jul 31, 2024
StartActual
Oct 5, 2023
Primary completionEst.
Nov 7, 2025
CompletionEst.
Nov 7, 2025
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06531317
Lead sponsor
Institut Guttmann
Collaborators
Castellers de la Vila de Gràcia
Responsible party
Dolors Soler (PhD, Principal Investigator, Institut Guttmann) — Principal investigator
First posted
Jul 31, 2024
Start date
Oct 5, 2023
Primary completion
Nov 7, 2025 (estimated)
Completion
Nov 7, 2025 (estimated)
Last update
Jul 31, 2024

Study contacts

Dolors Soler Fernandez, PhD
Contact
dsoler@guttmann.com
+34934977700 ext. 2195
Dolors Soler, PhD
principal investigator · Institut Guttmann

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion